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PTPN22 Is Genetically Associated with Risk of
Generalized Vitiligo, but CTLA4 Is Not
Greggory S. LaBerge1, Dorothy C. Bennett2, Pamela R. Fain1,3 and Richard A. Spritz1,4
Generalized vitiligo is an acquired, multifactorial, polygenic disease in which depigmented spots of skin,
overlying hair, and mucus membranes result from autoimmune-mediated loss of melanocytes from affected
areas. We examined single-nucleotide polymorphisms (SNPs) in the PTPN22 and CTLA4 genes in 126 Caucasian
families with multiple cases of generalized vitiligo and associated autoimmune diseases, using a family-based
association study design. The PTPN22 1858T allele of SNP rs2476601 is significantly associated both with
generalized vitiligo and with an expanded autoimmunity phenotype. Individuals carrying the PTPN22 1858T
allele had an allelic odds ratio (OR) of 2.16 for generalized vitiligo and a genotypic OR of 2.35 as C/T
heterozygotes. Similarly, individuals carrying the PTPN22 1858T allele had an allelic OR of 2.05 for the expanded
autoimmunity phenotype, and a genotypic OR of 2.19 for C/T heterozygotes. Examination of five SNPs in the
CTLA4 gene (rs1863800, rs231775, rs3087243, rs11571302, rs11571297, rs10932037) in the same 126 families yielded
no evidence of allelic or genotypic association with either generalized vitiligo or the expanded autoimmune
phenotype. These results implicate PTPN22 in mediating susceptibility to generalized vitiligo and associated
autoimmune diseases, but do not support a role for CTLA4.
Journal of Investigative Dermatology (2008) 128, 1757–1762; doi:10.1038/sj.jid.5701233; published online 17 January 2008
INTRODUCTION
Generalized vitiligo is an acquired, non-contagious disorder
in which progressive, patchy loss of pigmentation of skin,
overlying hair, and mucous membranes results from loss of
melanocytes from the involved areas (reviewed in Hann and
Nordlund, 2000; Nordlund et al., 2006). Known for
thousands of years because of its visually evident phenotype,
vitiligo is the most common pigmentation disorder, affecting
about 0.4% of Caucasians (Howitz et al., 1977) and
occurring with generally similar frequency in other popula-
tions (for example, Das et al., 1985a; Lu et al., 2007). Several
different etiologic hypotheses have been suggested for
generalized vitiligo (reviewed in Nordlund et al., 2006), the
most compelling of which involves a combination of
unknown environmental and genetic factors interacting to
contribute to autoimmune melanocyte destruction.
Most cases of generalized vitiligo occur sporadically,
although about 15–20% of patients report one or more
affected first-degree relatives. Typically, familial aggregation
of generalized vitiligo cases occurs in a non-Mendelian
pattern that is suggestive of polygenic, multifactorial inheri-
tance (Mehta et al., 1973; Carnevale et al., 1980; Hafez et al.,
1983; Das et al., 1985a, b; Majumder et al., 1988, 1993;
Bhatia et al., 1992; Nath et al., 1994; Alkhateeb et al., 2003;
LaBerge et al., 2005; Sun et al., 2006), and formal genetic
segregation analyses have indicated that multiple major loci
contribute to vitiligo susceptibility in a complex interactive
manner (Majumder et al., 1993; Nath et al., 1994; Sun et al.,
2006). Furthermore, patients with generalized vitiligo are also
at increased risk of developing other autoimmune diseases,
particularly autoimmune thyroid disease (Graves’ disease and
autoimmune hypothyroidism), rheumatoid arthritis, psoriasis,
latent autoimmune diabetes of adults, pernicious anemia,
Addison’s disease, and systemic lupus erythematosus
(Alkhateeb et al., 2003; LaBerge et al., 2005). These same
diseases also occur at increased frequencies in vitiligo
patients’ first-degree relatives, suggesting that susceptibility
to this group of autoimmune diseases is genetically
determined.
Genetic linkage and association studies have implicated a
number of different genes in susceptibility to generalized
vitiligo (reviewed in Spritz, 2007), including several that are
thought to play primary roles in the development of
autoimmunity. These include the major histocompatibility
complex (for example, Foley et al., 1983; Finco et al., 1991;
Orecchia et al., 1992; Ando et al., 1993; Schallreuter et al.,
1993; al-Fouzan et al., 1995; Zamani et al., 2001; Arcos-
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Burgos et al., 2002; Tastan et al., 2004; Fain et al., 2006; Xia
et al., 2006; Liu et al., 2007), CTLA4 (Kemp et al., 1999;
Blomhoff et al., 2005, Itirli et al., 2005), and PTPN22 (Canton
et al., 2005), and NALP1 (Jin et al., 2007a, b). Association of
vitiligo with PTPN22 and CTLA4 is based on small case–-
control studies, a study design that is notoriously subject to
both false-positive and false-negative errors due to population
admixture and stratification (Hirschhorn et al., 2002). To more
rigorously test the association of vitiligo with variation in
PTPN22 and CTLA4, we carried out family-based association
analyses of CTLA4 and PTPN22 single-nucleotide polymorph-
isms (SNPs) in 126 Caucasian families with multiple cases of
generalized vitiligo, which included the same families in
which we previously showed association to HLA markers (Fain
et al., 2006) and NALP1 (Jin et al., 2007a).
RESULTS
Family-based association analysis of PTPN22
We genotyped rs2476601 (PTPN22 risk allele 1858T) in 712
individuals from 126 Caucasian extended families with
multiple cases of vitiligo as well as other autoimmune
diseases, derived from the United States and the United
Kingdom (Alkhateeb et al., 2003; LaBerge et al., 2005; Jin
et al., 2007a). SNP rs2476601 was found to be in Hardy–
Weinberg equilibrium in founders (individuals with no
parents specified in the pedigree) in the 126 study families
(Table 1).
As shown in Table 2, we found that the high-risk 1858T
allele of rs2476601 was significantly associated (P¼0.0048)
with generalized vitiligo in the 126 study families. Genotypic
analysis showed that the rs2476601 heterozygous C/T
genotype was highly associated with vitiligo (P¼0.0012).
The PTPN22 high-risk 1858T allele showed allelic associa-
tion with generalized vitiligo [P¼0.024, odds ratio (OR) 2.16
(95% confidence interval (CI) 1.22–3.82)] (Table 2) from
conditional logistic regression analysis.
We also tested an expanded autoimmunity phenotype
that included all of the autoimmune diseases with which
vitiligo is epidemiologically associated (autoimmune thyroid
disease, rheumatoid arthritis, psoriasis, adult-onset autoim-
mune diabetes mellitus, pernicious anemia, systemic lupus
erythematosus, Addison’s disease), considering any indivi-
dual with either vitiligo or any other of these autoimmune
diseases as ‘‘affected’’. As shown in Table 2, the rs2476601
1858T allele also showed allelic association (P¼0.0042)
with this expanded autoimmunity phenotype, which was
confirmed by conditional logistic regression analysis
[P¼ 0.03, OR 2.05 (95% CI 1.19–3.53)]. Genotypic analysis,
presented in Table 3, showed that the rs2476601 C/T
genotype is significantly associated with the expanded
autoimmunity phenotype (P¼0.003), although association
with the T/T genotype was not significant (P¼0.750).
Conditional logistic regression analysis provided very
similar results, showing significant association of the C/T
heterozygote with the autoimmune disease phenotype
[P¼ 0.03, OR 2.19 (95% CI 1.20–3.97)], but non-significant
association of the T/T homozygote [P¼ 0.14, OR 3.22
(95% CI 0.68–15.27)].
Family-based association analysis of CTLA4
We also examined six SNPs in the CTLA4 gene (rs1863800,
rs231775, rs3087243, rs11571302, rs11571297,
rs10932037) for association with generalized vitiligo and
the expanded vitiligo-associated autoimmune phenotype in
these families. None of the CTLA4 SNPs tested exhibited
either allelic (Table 2) or genotypic (Table 3) association with
either generalized vitiligo or with the expanded autoimmu-
nity phenotype. All but one of these SNPs clustered into a
single linkage disequilibrium (LD) block (data not shown),
and no multiple testing corrections were applied to the
nominal P-value threshold (P¼0.05) due to lack of any
apparent association with disease.
DISCUSSION
We have carried out family-based association analyses of
PTPN22 and CTLA4 SNPs in 126 Caucasian extended
families with multiplex cases of vitiligo as well as other
autoimmune diseases, confirming the association of general-
ized vitiligo with the functional PTPN22 1858T (R620W)-
variant allele (OR 2.16, 95% CI 1.22–3.82) and the
heterozygous C/T genotype (OR 2.35, 95% CI 1.25–4.43).
Furthermore, we find that the PTPN22 1858T allele and C/T
genotype are also associated with an expanded autoimmunity
phenotype (allelic OR 2.05, 95% CI 1.19–3.53; genotypic OR
2.19, 95% CI 1.20–3.97) that includes generalized vitiligo or
Table 1. Results of Hardy–Weinberg equilibrium
(HWE) analysis of SNP genotypes among founders
from 126 multiplex vitiligo-autoimmune disease
families
SNP
Observed genotypes
in founders HWE P-value
PTPN22
rs2476601 T/T 2
C/T 34
C/C 104
0.9170
CTLA4
rs1863800 T/T 19
C/T 74
C/C 45
0.4210
rs231775 G/G 41
A/G 73
A/A 25
0.7492
rs3087243 A/A 23
A/G 76
G/G 40
0.4304
rs11571302 A/A 24
A/C 75
C/C 38
0.4602
rs11571297 G/G 29
A/G 75
A/A 34
0.5830
rs10932037 T/T 4
C/T 27
C/C 109
0.3750
SNP, single-nucleotide polymorphism.
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any of the other autoimmune diseases with which vitiligo
is epidemiologically associated (Alkhateeb et al., 2003;
LaBerge et al., 2005). These findings strongly support a
causal role for the PTPN22 1858T allele of rs2476601 (or
another variant with which 1858T is in close LD) in
susceptibility to both generalized vitiligo and these other
autoimmune diseases. We found no association of the
PTPN22 rs2476601 homozygous T/T genotype with either
generalized vitiligo or the expanded autoimmune phenotype,
most likely due to limited power resulting from the low
frequency of the T allele (0.13 in this study) and the
consequent small number of T/T homozygotes observed (8
of 712 individuals genotyped).
However, our analyses of the CTLA4 SNPs showed no
apparent allelic or genotypic association with either general-
ized vitiligo or the expanded autoimmunity phenotype. These
results are in contrast with previous reports of genetic
association of CTLA4 markers with vitiligo based on small
case–control studies (Kemp et al., 1999; Blomhoff et al.,
2005; Itirli et al., 2005). Kemp et al. (1999) reported the
association of the 106-bp allele of a microsatellite poly-
morphism in the CTLA4 3’-untranslated region with vitiligo
(especially autoimmune-associated) in 74 European
Caucasian patients versus 173 controls. The same group
(Blomhoff et al., 2005) subsequently reported the association
of CTLA4 SNPs MH30 (23 kb 50 of the CTLA4 gene),
rs3087243, rs11571302, and rs7565213 with vitiligo in 27
European Caucasian patients with associated autoimmune
disease versus 140 controls; it is not clear whether the case
and control cohorts in these two studies were independent.
Itirli et al. (2005) reported the association of the 96-bp allele
of the same CTLA4 microsatellite in 36 Turkish patients
versus 100 controls. It may be that these previous ‘‘associa-
tions’’ represent spurious false-positive results, due to either
occult population stratification (reviewed in Hirschhorn
et al., 2002) or the very small sample size and highly
unbalanced numbers of cases and controls in both studies.
Furthermore, Blomhoff et al. (2005) did not correct for
multiple testing, which would have rendered the reported
CTLA4 associations insignificant. Itirli et al. (2005) reported
significance based on the observation of only four vitiligo
patients versus two controls with the 96-bp allele, whereas
the 112-bp allele, which showed the largest difference in
allele frequency between cases and controls, was not
significant, indicating that ‘‘significance’’ of the 96-bp allele
almost certainly represents statistical fluctuation due to the
very small number of observations.
PTPN22 and CTLA4 are thought to function as general
autoimmunity susceptibility loci (Brand et al., 2005; Greger-
sen et al., 2006). The PTPN22 1858T variant results in an
arginine to tryptophan substitution that disrupts interaction
between Lyp and Csk protein tyrosine kinases, dis-inhibiting
T-cell activation (Siminovitch, 2004) and perhaps thereby
increasing susceptibility to autoimmune disease (Brand et al.,
2005). The PTPN22 1858T variant has been associated with
type 1 diabetes, rheumatoid arthritis, systemic lupus erythe-
matosus, Graves’ disease (Bottini et al., 2004; Siminovitch,
2004; Criswell et al., 2005; Zhernakova et al., 2005), and
vitiligo (Canton et al., 2005). In contrast, studies of patients
with psoriasis and multiple sclerosis showed no association
with the PTPN22 risk allele in two family-based studies
(Criswell et al., 2005; Nistor et al., 2005), suggesting that
PTPN22 may not truly be associated with these diseases.
Our study utilized a family-based design to test association
of PTPN22 and CTLA4 with generalized vitiligo, an approach
that is more rigorous than previous case–control studies of
these genes in vitiligo. Our findings demonstrate that PTPN22
can be included along with HLA and NALP1 among those
genes confirmed to play a role in polygenic susceptibility to
generalized vitiligo, but do not support a role for CTLA4.
MATERIALS AND METHODS
Subjects
Peripheral blood or saliva samples were obtained from 712
individuals from 126 extended families with multiplex cases of
generalized vitiligo as well as other autoimmune diseases, derived
from the United States and United Kingdom. All families were of
Caucasian origin (as self-reported) and had two or more family
members with generalized vitiligo and at least one family member
with one or more other autoimmune disease with which generalized
vitiligo is epidemiologically associated (autoimmune thyroid dis-
ease, latent autoimmune diabetes in adults, psoriasis, pernicious
anemia, systemic lupus erythematosus, rheumatoid arthritis,
Table 2. Allelic association analyses of PTPN22 and
CTLA4 SNPs
SNP
FBAT1(P-
value)
Regression on
alleles (P-value)
Odds ratio
(95% CI)
Vitiligo
PTPN22
rs2476601 0.00482 0.0242 2.16 (1.22–3.82)
CTLA4
rs1863800 0.3742 0.495 0.89 (0.63–1.24)
rs231775 0.5440 0.592 1.09 (0.79–1.52)
rs3087243 0.3518 0.683 0.934 (0.67–1.30)
rs11571302 0.3628 0.930 0.986 (0.71–1.36)
rs11571297 0.3942 0.858 1.03 (0.74–1.44)
rs10932037 0.8688 1.00 1.00 (0.61–1.65)
Expanded autoimmunity phenotype
PTPN22
rs2476601 0.00422 0.032 2.05 (1.19–3.53)
CTLA4
rs1863800 0.2907 0.305 0.85 (0.62–1.16)
rs231775 0.4198 0.310 0.85 (0.62–1.16)
rs3087243 0.2460 0.370 0.87 (0.63–1.18)
rs11571302 0.2655 0.578 0.92 (0.67–1.25)
rs11571297 0.2920 0.465 1.13 (0.82–1.56)
rs10932037 0.8858 0.809 0.94 (0.59–1.52)
CI, confidence interval; FBAT, family-based association test; SNP, single-
nucleotide polymorphism.
1P-values based on FBAT additive model.
2P-values corrected for three independent tests: two LD blocks in CTLA4
and one SNP in PTPN22.
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Addison’s disease; Alkhateeb et al., 2003; LaBerge et al., 2005).
Diagnostic criteria for generalized vitiligo were consistent with those
of the Vitiligo European Task Force (Taı¨eb and Picardo, 2007).
Exclusion criteria were atypical lesion distribution, congenital or
static skin depigmentation (for example, birthmarks, piebaldism,
Waardenburg syndrome), depigmentation secondary to the use of
melanocytotoxic chemicals, inflammatory skin diseases (systemic
lupus erythematosus, lichen planus, psoriasis), and post-infectious or
post-traumatic causes.
All available affected and unaffected family members completed
a clinical history questionnaire reporting vitiligo age of onset and
course of treatment, and a checklist of approximately 50 auto-
immune and autoinflammatory diseases. Each vitiligo patient
completed a skin-lesion map. All data were reviewed by study
investigators and staff, and individuals in whom diagnoses were
uncertain based on standard diagnostic criteria (Nordlund et al.,
2006) were excluded from the study. This study conformed to the
Declaration of Helsinki Principles and was approved by the
Colorado Multiple Institutional Review Board and the South East
Research Ethics Committee. Written, informed consent was provided
by all study participants.
SNP genotyping
DNA was isolated from peripheral blood using a genomic DNA
purification kit (Purgene, Gentra Systems) or from saliva obtained
using the DNA self-collection kit (Oragene; DNA Genotek, Ottawa,
Ontario, Canada). Genotyping was carried out for PTPN22-
rs2476601 (1858C/T), and CTLA4-rs1863800, rs231775 (þ 49G),
rs3087243 (CT60), rs11571302 (JO31), rs11571297 (JO27_1),
rs10932037 (CTIC154_1) in 10-ml PCR reaction volumes with
20 ng genomic DNA using standard methods. SNP alleles were
detected with the Applied Biosystems (ABI, Foster City, CA) PRISM
SNaPshot Multiplex Kit using an ABI 3130 Genetic Analyzer.
Automated genotyping was performed using ABI Genemapper
version 3.7 software; all genotypes were manually checked for
accuracy and allele calling consistency. Mendelian inheritance of all
markers was checked through all levels of PedCheck (O’Connell and
Weeks, 1998). Haplotype analysis of CTLA4 SNPs was carried out
using the error-screening routine of Merlin, version 1.0.0 (Abecasis
et al., 2002).
Statistical analyses
Deviations from expected Hardy–Weinberg proportions were tested
for each SNP in founders (no parents in the pedigree) and in persons
not in the lineage in all 126 families using w2-analysis, considering
Po0.05 significant. Calculation of LD between CTLA4 SNPs was
performed using Haploview software (Barrett et al., 2005), version
3.32, with haplotype blocks being determined by the method of
Gabriel et al. (2002). Single-locus association analyses of each SNP
were carried out using the family-based association test (Horvath
et al., 2001). Conditional logistic regression analysis was carried out
using STATA, version 9.2, which uses family-based data to
create a matched pseudo case–control data set, test for allelic or
genotypic association and estimate an OR for disease risk (Cordell
and Clayton, 2002). Nominally significant P-values (o0.05) were
corrected for three independent tests based on LD analysis, using
Haploview (two LD blocks defined in the CTLA4 gene and one SNP
in PTPN22).
Table 3. Genotypic association analyses of PTPN22
and CTLA4 SNPs
SNP Genotype
FBAT1
(P-value)
Regression on
genotypes
(P-value)
Odds ratio
(95% CI)
Vitiligo
PTPN22
rs2476601 T/T 0.814 0.126 3.42 (0.71–16.54)
C/T 0.00122 0.0242 2.35 (1.25–4.43)
C/C 0.999 Referent
CTLA4
rs1863800 T/T 0.807 0.542 0.797 (0.385–1.65)
C/T 0.488 0.576 0.886 (0.579–1.35)
C/C 0.327 Referent
rs231775 A/A 0.408 0.592 0.830 (0.419–1.64)
A/G 0.563 0.762 1.08 (0.657–1.77)
G/G 0.944 Referent
rs3087243 A/A 0.732 0.652 0.854 (0.430–1.70)
A/G 0.552 0.922 0.978 (0.623–1.53)
G/G 0.309 Referent
rs11571302 A/A 0.448 0.752 0.892 (0.440–1.81)
A/C 0.989 0.523 1.16 (0.738–1.82)
C/C 0.528 Referent
rs11571297 G/G 0.567 0.706 1.15 (0.553–2.40)
A/G 0.957 0.325 1.36 (0.740–2.48)
A/A 0.473 Referent
rs10932037 T/T 0.848 1.00 1.00 (0.234–4.28)
C/T 0.751 1.00 1.00 (0.572–1.75)
C/C 0.799 Referent
Expanded autoimmunity phenotype
PTPN22
rs2476601 T/T 0.750 0.140 3.22 (0.68 –15.27)
C/T 0.0032 0.032 2.19 (1.20 – 3.97)
C/C 0.999 Referent
CTLA4
rs1863800 T/T 0.636 0.379 0.734 (0.368–1.46)
C/T 0.553 0.358 0.829 (0.555–1.24)
C/C 0.299 Referent
rs231775 A/A 0.187 0.310 0.712 (0.369–1.37)
A/G 0.271 0.933 1.02 (0.638–1.63)
G/G 0.896 Referent
rs3087243 A/A 0.557 0.372 0.748 (0.394–1.42)
A/G 0.619 0.550 0.876 (0.568–1.35)
G/G 0.256 Referent
rs11571302 A/A 0.371 0.506 0.801 (0.416–1.54)
A/C 0.992 0.955 1.01 (0.656–1.56)
C/C 0.426 Referent
rs11571297 G/G 0.454 0.418 1.32 (0.672–2.60)
A/G 0.987 0.334 1.31 (0.759–2.24)
A/A 0.403 Referent
rs10932037 T/T 0.784 0.942 0.948 (0.223–4.02)
C/T 0.965 0.789 0.930 (0.549–1.58)
C/C 0.955 Referent
CI, confidence interval; FBAT, family-based association test; SNP, single-
nucleotide polymorphism.
1P-values based on FBAT genotype model.
2P-values corrected for 3 independent tests: 2 LD blocks in CTLA4 and 1
SNP in PTPN22.
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